i think u misunderstood the phrase "30% higher than FYE 31 Mar 09".

BIG is trying to highlight that [the estimate for FY2010 (US$90-100m)] is 30% higher than [the estimate for FY2009 (US$65-75m)] .

The point i'm trying to point out is how can you use FY2010 guidance to estimate Q4FY2009???

FY2009 = 1st April 2008 to 31st March 2009

FY2010 = 1st April 2009 to 31st March 2010

FYE 31 March 2010 Financial Guidance - Revenues

• Estimated product revenues ranging from US$90.0 million to

US$100.0 million

– 30% higher than guidance provided for FYE 31 March 2009

– Significant growth increase in DES revenues

– Slower growth for other IVP products

– CCP sales remain flat

– Licensee revenues not included in product revenues

estimates

XTENT's Customizable Drug-Eluting Stent Gets European CE Mark Approval

Company Needs Financing to Avoid Scheduled Layoffs

March 20, 2009

n      Hopefully, for the innovative stent manufactured by XTENT, Inc. (Nasdaq: XTNT), yesterday's European approval has not come too late.

n     

 

n       On Thursday, the company announced that it has received CE Mark approval for its CUSTOM NX drug-eluting stent (DES) System.

n     

 

n       The CE Mark indicates that the CUSTOM NX DES System may be marketed in the European Union as well as other countries that recognize the CE Mark and that the product complies with applicable safety and quality standards.

n     

 

n       The approval includes both the Custom NX 36, a 36 millimeter stent and the Custom NX 60, a 60 millimeter stent.

On January 23 the company, running out of cash, announced that it would be forced to terminate all but nine of its employees as of Monday, March 23, unless it found a buyer or resolved its economic difficulties in other ways.

 Whether this approval is one of the "other ways" is yet to be seen. The company now needs cash and financial backing in order to manufacture and market its stent.

 

XTENT's stock price closed today at $.70, up 350% from its low in January, but a fraction of the $16 it traded for when it went public two years ago.

 The company's situation has much to do with the current economic landscape and shrinking of credit, and less to do with the company's main product: the customizable stent -- a concept that has much merit.

One difficulty that interventional cardiologists face is choosing the proper length of stent for a blockage. Too short a stent doesn't completely cover the diseased area, a situation which become high risk for increased cell growth around its edges and subsequent restenosis (blockage).

Likewise, if the stent is too long, metal is being placed in a healthy section of the artery, something which also increases the risk of blockage.

With the XTENT, physicians can tailor the length of the stent during the procedure.

 The XTENT is a cobalt-chromium metal stent, covered with a biodegradable coating which eludes Biolimus A9™, a drug which suppresses excess cellular growth, licensed from Biosensors.

Regarding today's news, President and CEO of XTENT, Gregory D. Casciaro, stated:

"Receipt of the CE Mark is an important accomplishment and a validation of the strength of our clinical data. It is a tribute to the hard work and dedication of our people as well as the collaborative effort of our drug coating provider, Biosensors.

 We look forward to the opportunity to bring this revolutionary new technology to patients and physicians throughout the European Union."

 

The CE Mark approval of the Custom NX DES System represents a number of important firsts in the treatment of coronary artery disease including:

Approval of the first ever customizable stent system

Approval of the Custom NX 60, the longest coronary stent system ever to be approved for sale

Approval of the first stent system to allow treatment of multiple lesions using one catheter

Approval of the first stent system to incorporate a post dilation feature on the delivery catheter

The Custom NX DES System has not been approved for sale in the United States. To gain U.S. approval, the company would need to run a large clinical trial, well beyond its current capabilities.

 It has been speculated that XTENT would be a bargain acquisition by one of the four major stent companies, Boston Scientific, Johnson & Johnson/Cordis, Abbott or Medtronic.

 

 However, since January, when the company's total market valuation was $5 million, none of the four have made offers, and the company's value is now at $16 million and gaining

 

January 23, 2009 -- In an announcement today, Xtent Inc. (NASDAQ: XTNT) located in Menlo Park, California, stated that it is engaging the services of an investment bank to help the company pursue strategic alternatives, possible sale of some or all of the company's assets, or other type of acquisition. And of it 121 employees, all but nine have received termination notices, effective March 23.

CEO and President, Gregory D. Casciaro, stated:

"Given the continued challenges faced in the capital markets, we believe it is in the best interests of the shareholders to consider strategic options. We remain confident in the benefits of customizable stenting and are assessing all viable options available to us in order to maximize the value of our assets. Effective immediately, we are executing plans to reduce activities and costs to a critical minimum, including a significant reduction in headcount in order to preserve cash and flexibility."

When Xtent went public in two years ago, its stock traded at over $16. Today Xtent closed at $.20, a mere 1% of its original value. However, the company's situation has much to do with the current economic landscape and shrinking of credit, and less to do with the company's main product: the customizable stent.

One difficulty the interventional cardiologists face is choosing the proper length stent for a blockage. Too short a stent doesn't completely cover the diseased area, a situation which become high risk for increased cell growth around its edges and subsequent restenosis (blockage). Likewise, if the stent is too long, metal is being placed in too large a healthy section of the artery, something which also increases the risk of blockage. With the Xtent, physicians can tailor, on the spot, the length of the stent during the procedure. The Xtent is a cobalt-chromium metal stent, covered with a biodegradable coating which eludes Biolimus A9™, a drug which suppresses excess cellular growth, licensed from Biosensors.

To gain U.S. approval, the company would need to run a large clinical trial, well beyond its current capabilities. However, with its current valuation at $5 million, Xtent might be a bargain for one of the larger device manufacturers (Abbott Vascular, for example, is a 15 minute drive from Xtent headquarters). Should such a scenario evolve, it is possible that the 119 employees would not be laid off. Stay tuned....

 

    --  Approval of the first ever customizable stent system
    --  Approval of the Custom NX 60, the longest coronary stent system ever to
        be approved for sale
    --  Approval of the first stent system to allow treatment of multiple
        lesions using one catheter
    --  Approval of the first stent system to incorporate a post dilation
        feature on the delivery catheter

http://www.xtentinc.com

I think BIG is covering back the gap at 0.375 .... especially now with all the bad news .... hope it will be a touch & go and bounce up all the way again ... then there will be no down gap to be filled. Instead, there are some upward gaps waiting to be filled.

Above not an inducement to trade.